

Generic immunosuppressants have reduced costs after organ transplantation

February 28 2019

The introduction of generic versions of immunosuppressive drugs has resulted in substantial cost savings for transplant patients and Medicare, according to a study appearing in an upcoming issue of the *Clinical Journal of the American Society of Nephrology (CJASN)*.

Individuals who receive [organ transplants](#) must take life-long immunosuppressive medications to prevent rejection. Currently, Medicare provides coverage for immunosuppressive medication for the first 3 years following a kidney transplant, and patients can face significant out-of-pocket medication costs after that time. This can prevent some patients from filling necessary prescriptions, potentially leading to poor health outcomes.

About a decade ago, generic formulations of the two most commonly used immunosuppressive medications in the United States, tacrolimus and mycophenolate, became available, providing the potential to reduce costs for transplant recipients and payers.

To investigate the impact of generic introduction on payments for immunosuppressants by patients and Medicare, Margaret E. Helmuth, MA (Arbor Research Collaborative for Health) and her colleagues assessed the [cost savings](#) from substitution with generic immunosuppressive medications for [organ transplant recipients](#) and the Medicare Part D program. The team reported on the average annualized Medicare Part D plan payments, average annualized payments by the Medicare Part D low-income subsidy program, and average annualized

out-of-pocket payments by patients for brand-name and generic tacrolimus and mycophenolate.

The investigators studied immunosuppressant medication costs for transplant recipients who received a kidney, liver, or [heart transplant](#) between 1987 and 2013 and filled prescriptions through Medicare Part D for tacrolimus or mycophenolate between 2008 and 2013. Overall, payments decreased for both patients (by 63%-79% for patients not receiving the low-income subsidy and 24%-44% for those receiving the subsidy) and Medicare Part D plans (by 48%-67%) across the 3 organs and 2 drugs over the 5 years studied.

For transplant recipients not receiving the low-income subsidy, the researchers observed declines in average out-of-pocket payments of \$1,000 to \$1,750 per patient per year between 2008 and 2013, depending on the organ type and drug. For the Medicare program, they observed savings of \$1,500 to \$4,500 per patient per year in Part D plan payments between 2008 and 2013, and additional savings to Medicare of \$400 to \$1,500 per low-income subsidy recipient per year over the same time period.

In addition, the investigators observed large differences in average yearly out-of-pocket payments for immunosuppressive medications between Part D beneficiaries who did and did not qualify for the Medicare low-income subsidy. The finding suggests that recipients with resources just above the threshold to qualify for this subsidy may experience considerable financial strain.

"The debate regarding universal coverage of immunosuppressive medications for [transplant recipients](#) has been ongoing for more than 30 years," said Helmuth. "We believe that this research will help inform ongoing national discussions about the funding of post-transplant [immunosuppressive medication](#) coverage."

In an accompanying Patient Voice editorial, Cher Thomas, RDH, a [kidney transplant](#) recipient celebrating her twentieth anniversary after transplantation, noted that in the early months after receiving a kidney, her copay on just 1 [medication](#) was \$500, and this was not for an immunosuppressive drug. Now all of her medications are generic, and she is thankful for saving money on her immunosuppressants. She also raised a number of concerns about the study's design and findings, as well as the role of insurance companies in deciding which generic medications can be prescribed to [patients](#).

More information: "Secular Trends in the Cost of Immunosuppressants After Solid Organ Transplantation in the United States," *Clinical Journal of the American Society of Nephrology* (2019). DOI: [10.2215/CJN.10590918](https://doi.org/10.2215/CJN.10590918)

Provided by American Society of Nephrology

Citation: Generic immunosuppressants have reduced costs after organ transplantation (2019, February 28) retrieved 3 May 2024 from <https://medicalxpress.com/news/2019-02-immunosuppressants-transplantation.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--